Vyne Therapeutics
Price & Volume
Stats
See moreOpen | $1.38 |
Previous Close | $1.41 |
Day Range | $1.29-$1.38 |
52W Range | $1.28-$4.30 |
Market Cap | $21.9M |
Shares Short | 191,069 |
Financials
See moreRevenue (12 Mos) | $501,000 |
Revenue Growth (YoY) | 10.5% |
Gross Profit (12 Mos) | $501,000 |
Diluted EPS | -$0.93 |
News
See moreYahoo Finance • last month
VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
Yahoo Finance • 2 months ago
VYNE Therapeutics to Participate in March Investor Conferences
Yahoo Finance • 2 months ago
VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis
Yahoo Finance • last year
VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
About
CEO | Mr. David T. Domzalski |
CFO | Mr. Tyler Zeronda CPA |
Address | 685 Route 202/206 N, Bridgewater, NJ, United States, 08807 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 13 |
